Life Sciences Jobs under DBT INDIGO funded project at SJRI
27 March 2026

Life Sciences Jobs under DBT INDIGO funded project at SJRI

Masters in Life Sciences with minimum 4 years experience. Ability to work independently on a focussed programme of work and be collegiate within a wider team of immunologists.
27 March 2026
ANRF Life Sciences Fellowship at Central University of Punjab
M.Sc. in any branch of the life sciences or equivalent with at least 55% marks. Candidate with a qualified GATE, NET, will be preferred
27 March 2026
Recruitment for Assistant Professor at All India Institute of Hygiene & Public Health
Masters degree in Organic Chemistry or Inorganic Chemistry or Physiology of a recognized University or equivalent.
27 March 2026
Clinical Research Coordinator Job at Tata Memorial Centre
Graduate Degree in Sciences / B.Pharm & Post Graduate Diploma in Clinical Research is Mandatory.
27 March 2026
Macleods Hiring Research Associate
Experience in solid oral dosage & liquid orals in formulation & development department for regulated market.
27 March 2026
Intas Pharma Walk In Drive at Baddi, Jobs in Quality Control, Manufacturing
Intas is one of the leading multinational pharmaceutical formulation development, manufacturing and marketing companies in the world.
27 March 2026
Production and Packing Jobs at Alembic Pharmaceuticals
Handling Raw Material Stores & Finished Goods Stores. RM Dispensing as per production requirements. Stacking & Storage of materials.
27 March 2026
Novo Nordisk : Awiqli® approved in the USA
Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and exercise to improve glycaemic control (blood sugar) in adults living with type 2 diabetes.
27 March 2026
FDA Approves First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I

The U.S. Food and Drug Administration today approved Kresladi (marnetegragene autotemcel), the first gene therapy for the treatment of severe Leukocyte Adhesion Deficiency Type I (LAD-I). Kresladi is indicated for the treatment of pediatric patients with severe leukocyte adhesion deficiency I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen (HLA)-matched sibling donor for allogeneic hematopoietic stem cell transplant.

27 March 2026
ICMR Burden of Disease IITB Project Research Job at St. John's Research Institute
The objective of this component of the study is to estimate the national as well as subnational burden of NCDs in India using an integrated approach combining available health surveys, administrative data, and advanced statistical model as well as machine leaning methods.